

**Changes to the CalOptima Health Medi-Cal Physician Administered Drug (PAD) PA List and
OneCare Formulary
Pharmacy & Therapeutics Committee Meeting
May 21, 2026**

Effective Dates	Brand Name†	Generic Name	Drug Class	Strength	Dosage Form	Committee Action for Medi-Cal PAD PA List	Committee Action for OneCare Formulary
7/1/26	Sofdra	sofpironium bromide	Primary axillary hyperhidrosis	12.45%	Topical gel	N/A	Non-Formulary
7/1/26	Ensacove	ensartinib hydrochloride	Antineoplastic	25 mg, 100 mg	Capsule	N/A	PA Required (NSO), QL: 30/30 days
7/1/26	Sephience	sepiapterin	Phenylketonuria	250 mg and 1000 mg	Powder packet	N/A	Non-Formulary
7/1/26	Lequembli IQLIK	lecanemab-irmb	Alzheimer's disease	360 mg/1.8 mL	Auto-injector	N/A	PA Required
7/1/26	Brekiya	dihydroergotamine mesylate	Migraine and cluster headaches	1 mg/mL	Auto-injector	N/A	Non-Formulary
7/1/26	Enbumyst	bumetanide	Edema	0.5 mg/0.1 mL	Nasal spray	N/A	Non-Formulary
7/1/26	Forzinity	elamipretide HCl	Barth syndrome	280 mg/3.5 mL	Vial	N/A	PA Required
7/1/26	Redemplo	plozasiran sodium	Familial chylomicronemia syndrome	25 mg/0.5 mL	Syringe	N/A	PA Required, QL: 0.5 mL/90 days
7/1/26	Hyrnuo	sevabertinib	Antineoplastic	10 mg	Tablet	N/A	PA Required (NSO), QL: 120/30 days
7/1/26	Voyxact	sibeprenlimab-szsi	Immunoglobulin A nephropathy	400 mg/2 mL	Syringe	N/A	PA Required, QL: 2 mL/28 days
7/1/26	Wegovy	semaglutide	Cardiovascular disease and obesity/overweight	1.5 mg, 4 mg, 9 mg, 25 mg	Tablet	N/A	PA Required QL: 30/30 days
7/1/26	Cardamyst	etripamil	Paroxysmal supraventricular tachycardia	70 mg	Nasal spray	N/A	PA Required, QL: 2 devices/28 days
7/1/26	Aqvesme	mitapivat sulfate	Anemia in alpha- or beta-thalassemia	100 mg	Tablet	N/A	PA Required, QL: 60/30 days
7/1/26	Myqorzo	aficamten	Obstructive hypertrophic cardiomyopathy	5 mg, 10 mg, 15 mg, 20 mg	Tablet	N/A	PA Required, QL: 30/30 days

N/A = Not Applicable, NSO = New Starts Only, PA = Prior Authorization, QL = Quantity Limit, SL = Sublingual, SQ = Subcutaneous